The 12-week ANTHEM-UC Phase 2b trial marks a major expansion in the clinical development of Icotrokinra (formerly JNJ-2113). Moving beyond plaque psoriasis, these data demonstrate how targeted oral interleukin-23 receptor (IL-23R) peptide antagonism functions inside the inflamed colonic mucosa of patients with moderately-to-severely active ulcerative colitis.
⚡ Quick Summary: Icotrokinra ANTHEM-UC Trial Results
Quick Answer: In the Phase 2b ANTHEM-UC trial evaluating adults with moderately-to-severely active ulcerative colitis, once-daily oral icotrokinra 400 mg achieved a 63.5% clinical response rate (vs. 27.0% for placebo) and a 30.2% clinical remission rate (vs. 11.1% for placebo) at week 12. As a first-in-class oral macrocyclic peptide targeting the IL-23 receptor, icotrokinra demonstrated substantial mucosal healing and symptom relief in a once-daily tablet, matching injectable biologic benchmarks while avoiding the systemic liabilities of JAK inhibitors.
| Treatment Arm | Clinical Response (Wk 12) | Clinical Remission (Wk 12) | Primary Outcome Status |
|---|---|---|---|
| Icotrokinra 400 mg QD | 63.5% | 30.2% | Statistically significant vs. placebo (p < 0.05) |
| Icotrokinra Lower Doses | Positive dose-dependent trend | Numerical improvement | Did not achieve statistical significance |
| Placebo Control | 27.0% | 11.1% | Standardized control baseline |
| Safety / SAE Profile | Low, balanced across arms | No opportunistic infections | No JAK-associated cytopenias or MACE |
What Is the Compound? Mechanism of Targeted Oral IL-23R Blockade in IBD
Icotrokinra is an engineered, first-in-class oral macrocyclic peptide designed to bind with picomolar affinity to the interleukin-23 receptor (IL-23R). In ulcerative colitis, excessive production of IL-23 by antigen-presenting cells binds to IL-23R on pathogenic Th17 cells, innate lymphoid cells (ILC3), and natural killer T cells, triggering the release of tissue-destructive inflammatory cytokines including IL-17A, IL-17F, and IL-22.
Historically, achieving potent cytokine blockade in inflammatory bowel disease required parenterally administered monoclonal antibodies (such as ustekinumab or mirikizumab) via IV infusions or subcutaneous autoinjectors. Oral small-molecule alternatives, such as Janus kinase (JAK) inhibitors or S1P receptor modulators, often introduce broad, off-target systemic immunosuppression, leading to boxed warnings for herpes zoster reactivation, lipid elevations, and thromboembolic events. Icotrokinra bridges this therapeutic divide: its cyclized peptide architecture survives the enzymatic and acidic degradation of the human digestive tract, delivering biologic-level target selectivity directly to the intestinal lining via a once-daily oral tablet.
How the Study Worked: ANTHEM-UC Trial Design & Architecture
The ANTHEM-UC study was a randomized, double-blind, placebo-controlled Phase 2b dose-ranging trial designed to assess the clinical induction efficacy and safety of oral icotrokinra across four key domains:
1. High-Need Patient Population
Enrolled adult participants suffering from moderately-to-severely active ulcerative colitis who demonstrated intolerance or inadequate response to conventional therapies or prior biologic agents.
2. Stepped Dose-Ranging Design
Evaluated multiple once-daily oral dosing cohorts against placebo over a 12-week induction period to establish the minimum effective threshold and the optimal dose for Phase 3 progression.
3. Dual Symptom & Remission Criteria
Tracked primary clinical response alongside strict clinical remission criteria based on the modified Mayo score, separating symptomatic bowel improvement from complete disease control.
4. Objective Mucosal Evaluation
Secondary endpoints incorporated endoscopic mucosal inspection and histologic tissue scoring to confirm that symptom reductions were backed by physical resolution of intestinal ulcers.
Full study parameters and corporate regulatory disclosures are documented in the Johnson & Johnson ANTHEM-UC Primary Clinical Report.
Results and Key Findings: Clinical Induction and Dose-Dependent Remission
The 12-week primary reporting window revealed clear proof-of-concept for oral IL-23R blockade in colonic inflammation, highlighted by a strong dose-response gradient:
- Clinical Response at 400 mg: 63.5% of participants receiving the once-daily 400 mg dose achieved a confirmed clinical response at week 12, compared to 27.0% in the placebo group.
- Clinical Remission at 400 mg: 30.2% of patients in the 400 mg cohort achieved complete clinical remission, nearly triple the placebo rate of 11.1% (a statistically significant outcome, p < 0.05).
- Lower-Dose Remission Comparisons: While intermediate and lower doses demonstrated numerical separation in symptom reduction, their between-group differences in complete clinical remission did not reach conventional statistical significance, isolating 400 mg as the clear primary candidate for Phase 3 development.
- Endoscopic and Biomarker Normalization: In the 400 mg arm, patients exhibited marked reductions in objective biological markers of colonic injury, including fecal calprotectin and high-sensitivity C-reactive protein (hs-CRP), alongside visible endoscopic healing of the mucosal lining.
The Study in Plain English: Clinical Response vs. Deep Remission
Interpreting ulcerative colitis trial endpoints requires understanding the clinical hierarchy between feeling better and true tissue healing:
| Trial Metric | Clinical Definition (Modified Mayo Score) | Real-World Patient Meaning |
|---|---|---|
| Clinical Response | ≥30% and ≥2-point reduction in Mayo score, with ≥1-point drop in rectal bleeding | Noticeable symptomatic relief: fewer daily bowel movements and visibly reduced stool blood |
| Clinical Remission | Stool frequency subscore of 0 or 1, rectal bleeding score of 0, and endoscopic subscore ≤1 | Complete symptom quiescence: normalized bowel habits, zero bleeding, and inactive colitis |
| Endoscopic Improvement | Mayo endoscopic subscore of 0 (normal mucosal architecture) or 1 (mild erythema) | Physical healing of the intestinal lining; resolution of bleeding ulcerations and friability |
| Targeted Oral Peptide | Engineered macrocyclic peptide surviving gastric acid to bind mucosal IL-23R locally | Combines the convenience of a daily pill with the precision and safety of an injectable biologic |
Key Insights: What Makes the ANTHEM-UC Results Significant?
The findings from ANTHEM-UC provide critical insights into the future of oral peptide pharmacology and gastrointestinal medicine:
- Overcoming the Gut Degradation Barrier: Peptides have historically been considered unviable for oral IBD therapy due to dense proteolytic enzymes in the inflamed colon. Demonstrating 30.2% remission confirms that icotrokinra delivers biologically active concentrations directly to mucosal tissue.
- Biologic Efficacy in a Pill: A 30.2% 12-week clinical remission rate in moderately-to-severely active UC is directly comparable to the induction rates established by injectable anti-IL-23 and anti-TNF monoclonal antibodies, offering a needle-free alternative.
- Dose Precision Informs Phase 3: The lack of statistical significance at lower doses provides clear guidance for future registration programs. Phase 3 trials will center on the 400 mg once-daily exposure to ensure maximum mucosal saturation and maintenance of response.
Tolerability & The Complete Safety Profile
Throughout the 12-week induction phase, icotrokinra maintained an adverse event profile consistent with its targeted, non-systemic mechanism of action:
- Balanced Adverse Events: The overall incidence of treatment-emergent adverse events (TEAEs) was comparable between the active icotrokinra arms and the placebo cohort.
- Low Serious Adverse Event (SAE) Rates: Serious adverse events and discontinuations due to drug toxicity were rare, with no dose-dependent safety signals observed across any cohort.
- Absence of Small-Molecule Liabilities: Unlike pan-JAK or TYK2 inhibitors, icotrokinra was not associated with cytopenias (anemia or neutropenia), liver transaminase flares, opportunistic infections (such as systemic herpes zoster), or venous thromboembolism.
For official product monographs and dermatological approval background, reference the FDA Icotyde Approval & Clinical Trial Snapshot.
Synergistic Research Themes & Related Epithelial Peptides
When analyzing mucosal healing and cytokine-mediated barrier destruction, researchers explore complementary biological repair pathways:
- Metabolic & Intestinal Inflammation: Metabolic hormones interact directly with gut mucosal integrity. To explore incretin signaling in systemic inflammatory states, read: Joint Relief or Caloric Relief? GLP-1 in Arthritis & Psoriasis.
- Epithelial Anti-Inflammatory Peptides (KPV): In preclinical colitis models, the tripeptide KPV is studied for its ability to downregulate mucosal NF-κB and reduce inflammatory bowel edema: KPV Peptide Explained: Gut Barrier Action & Dosing Protocols.
- Vascular & Soft-Tissue Healing: While IL-23R blockade halts immune-mediated tissue destruction, research into mucosal re-epithelialization frequently examines the angiogenic mechanisms of the Wolverine Blend (BPC-157 / TB-500): What Is the Wolverine Blend? Synergy & Research Protocols.
What Patients and Clinicians Can Look Forward To
The successful completion of ANTHEM-UC sets the stage for a comprehensive global Phase 3 development program in ulcerative colitis. While icotrokinra is currently FDA-approved for plaque psoriasis under the brand name Icotyde, clinicians and researchers must remember that regulatory approval for psoriasis does not constitute approval for inflammatory bowel disease.
For patients with ulcerative colitis—many of whom face lifelong cyclic injections or the toxicity risks of non-selective immunosuppressants—the progression of an oral, gut-targeted IL-23R peptide represents an encouraging step toward needle-free, biologic-grade disease control.
Questions for the Next Stage of Research
As icotrokinra advances into Phase 3 clinical evaluation, key questions remain regarding its long-term performance in inflammatory bowel disease:
- Durability Through 52 Weeks: Will the 30.2% induction remission rate convert into durable, steroid-free maintenance of remission over 52 weeks of continuous once-daily therapy?
- Efficacy in Biologic-Experienced Cohorts: How will oral IL-23R blockade perform in refractory patients who have previously failed anti-TNF biologics, vedolizumab, or JAK inhibitors?
- Expansion into Crohn’s Disease: Will parallel Phase 3 trials in Crohn’s disease replicate this mucosal response in transmural, small-bowel inflammation?
Explore Our Research Tools
To assist researchers in tracking clinical calculations, reconstitution ratios, and experimental schedules, explore our laboratory software suite:
- Calculate volume measurements and concentration parameters with the interactive Peptide Calculator.
- Structure research intervals, timing windows, and observation phases inside the Protocol Builder.
- Log laboratory markers, baseline patient metrics, and analytical notes with the Protocol Tracker Tool.
Scientific References & Primary Trial Documents
- Johnson & Johnson: Icotrokinra Data in Ulcerative Colitis Show Potential for Standout Benefit in Once-Daily Pill (ANTHEM-UC Press Release)
- U.S. Food and Drug Administration (FDA): Drug Trials Snapshot — Icotyde (Icotrokinra)
- Joint Relief or Caloric Relief? GLP-1 in Arthritis & Psoriasis
Clinical Verdict: The Phase 2b ANTHEM-UC clinical trial confirms that oral icotrokinra 400 mg provides potent, statistically significant induction of clinical response (63.5%) and clinical remission (30.2%) in moderately-to-severely active ulcerative colitis. By pairing high-affinity IL-23 receptor antagonism with the convenience of an oral tablet, icotrokinra represents a potential breakthrough in gastroenterology, offering biologic-level mucosal healing without the systemic toxicities of traditional immunosuppressive agents.
← View all clinical research, trials & peptide analyses in our Blog Archive
